ObjectiveTo systematically review the diagnostic value of the combined test of serum CA153, CA125 and CEA in detection of breast cancer. MethodsClinical diagnostic tests about CA153, CA125 and CEA in patients with breast cancer were retrieved in PubMed, EMbase, CBM, The Cochrane Library (Issue 3, 2014), CNKI, VIP, and WanFang Data from January 1st, 2004 to April 16st, 2014. References of included literature were also retrieved. Literature screening according to the inclusion and exclusion criteria, data extraction and methodological quality assessment were completed by two reviewers independently. Meta-analysis was then conducted using Meta-Disc 1.4 software. ResultsA total of 21 studies involving 4 263 subjects were enrolled. In all studies, the results of meta-analysis indicated that:the DOR, AUC and Q index of the single test (CA153) were 18.71 (95%CI 11.62 to 30.11), 0.858 9, and 0.789 7; while those of the combined test (CA153, CA125 and CEA) were 37.95 (95%CI 21.97 to 65.57), 0.959 1, 0.903 1. Compared with the single test, the diagnostic efficacy of the combined test was higher (Z=3.675, P=0.001 5). ConclusionCompared with the detection of CA153 alone, the combined detection of CA125, CA153 and CEA has higher efficacy and accuracy in the diagnosis of breast cancer.
【摘要】目的探讨骨桥蛋白(OPN)联合血清CA125和CA199水平对子宫内膜异位症的诊断价值。方法2005年1月2008年12月采集45例子宫内膜异位症患者及45名健康妇女自愿捐赠的血清样品,分别采用ELISA法及化学发光法检测OPN、CA125、CA199水平。结果与健康妇女相比,子宫内膜异位症患者血清OPN和CA125、CA199含量明显升高(Plt;001)。重度组(美国生育学会分期Ⅲ、Ⅴ期)子宫内膜异位症患者OPN和CA125、CA199明显高于轻度组(Ⅰ、Ⅱ期)(Plt;001)。结论OPN、CA199可作为子宫内膜异位症诊断及病情监测的临床指标,联合CA125检测可提高其临床应用价值。
目的探讨血清CA153、CA125和CA19-9检测对乳腺癌早期诊断的价值。方法采用化学发光免疫法分别检测乳腺癌、乳腺良性疾病患者及正常健康体检者血清CA153、CA125和CA19-9的水平。结果乳腺癌患者血清的CA153、CA125和CA19-9的表达水平及表达阳性率均明显高于正常对照者和乳腺良性疾病患者(Plt;0.01)； 乳腺癌患者术后CA153、CA125及CA19-9表达水平较术前明显下降(Plt;0.01)，与正常对照者比较差异无统计学意义(Pgt;0.05)。结论肿瘤标志物CA153、CA125及CA19-9 对乳腺癌有一定的诊断价值，且可作为监测乳腺癌病情进展、评估治疗疗效及预后的指标。